Pharmaceutical Executive
AbelsonTaylor
QUESTIONS?
AbelsonTaylor
BRAND Psoriatic arthritis disease awareness CLIENT Amgen/Wyeth FROM LEFT: Andy McAfee, associate creative director; James Gillespie, senior copywriter; George Starr, senior art director; Holly Wright, senior account supervisor; Eric Pernod, associate creative director, art
The goal of the "Questions" print campaign was to create awareness among psoriasis patients about joint pain, drive them to the Web site MyPsoriasisConnection.com for more information, and encourage them to talk with their dermatologist.
The PSA is aimed at educating psoriasis patients who are also experiencing joint pain about psoriatic arthritis—and the fact that they could be at risk for permanent joint damage. "The ad quickly telegraphs to patients with psoriatic plaques, 'Hey, this ad is for me,' and to start that conversation with their dermatologist," says Andy McAfee, associate creative director. "This is an important educational message for patients, so we really wanted to be sure they didn't miss it."
Nearly four in 10 people with psoriasis have psoriatic arthritis. But often these folks never make the connection between their skin condition and joint pain. While the skin symptoms are more evident, patients tend to ignore the joint pain symptomatic of psoriatic arthritis.
The headline, along with the psoriatic plaques forming the question mark on the arm, represents a single-minded way to help patients realize that the question—"Is it actually psoriatic arthritis?"—is for them.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.